Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2004-02-17
2009-06-30
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S560000, C424S523000
Reexamination Certificate
active
07553870
ABSTRACT:
The use of polyunsaturated fatty acids of the ω-3 series such as eicosapentaenoic acid (EPA, C20:5ω-3), docosahexaenoic acid (DHA, C22:6ω-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.
REFERENCES:
patent: 5130061 (1992-07-01), Cornieri et al.
patent: 5378732 (1995-01-01), Horrobin et al.
patent: 5502077 (1996-03-01), Breivik et al.
patent: 5541225 (1996-07-01), Leaf et al.
patent: 5656667 (1997-08-01), Breivik et al.
patent: 5698594 (1997-12-01), Breivik et al.
patent: 5753703 (1998-05-01), Cavazza et al.
patent: 5760081 (1998-06-01), Leaf et al.
patent: 5776978 (1998-07-01), Burzzese
patent: 5859055 (1999-01-01), Horrobin et al.
patent: 5869714 (1999-02-01), Bruzzese
patent: 6008248 (1999-12-01), Pscherer et al.
patent: 6245811 (2001-06-01), Horrobin et al.
patent: 6284268 (2001-09-01), Mishra et al.
patent: 6670396 (2003-12-01), Serhan et al.
patent: 2003/0144219 (2003-07-01), Phinney et al.
patent: 2008/0269331 (2008-10-01), Shibuya
patent: 1082909 (1993-01-01), None
patent: 0409903 (1992-04-01), None
patent: 0 780 124 (1997-06-01), None
patent: 1 157 692 (2001-11-01), None
patent: 1157692 (2005-10-01), None
patent: 02/25447 (1988-07-01), None
patent: WO89/11521 (1989-11-01), None
patent: WO 00/32210 (2000-06-01), None
patent: WO00/48592 (2000-08-01), None
patent: WO 01/46115 (2001-06-01), None
patent: WO 01/60778 (2001-08-01), None
patent: WO02/058793 (2002-08-01), None
patent: WO 2008/066745 (2008-06-01), None
Harrison's Principles of Internal Medicine, 13th Ed., vol. 1, published 1994 by McGraw-Hill, Inc. (NY), pp. 1108-1116.
The Merck Manual of Diagnosis and Therapy, 14th Ed., published 1982 by Merck, Sharp & Dohme Research Laboratories (NJ), pp. 386-389 and 1036-1053.
R. Pakala, et al., Atherosclerosis 153, XP-002229283, pp. 47-57, “Vascular Smooth Muscle Cells Preloaded With Eicosapentaenoic Acid and Docosahexaenoic Acid Fail to Respond to Serotonin Stimulation”, 2000.
S. Takeo, et al., Molecular and Cellular Biochemistry 188, XP-008012809, pp. 199-208, “Effects of Long-Term Treatment With Eicosapentaenoic Acid on the Heart Subjected to Ischemia/Reperfusion and Hypoxia/Reoxygenation in Rats”, 1998.
R. B. Singh, et al., Cardiovascular Drugs and Therapy 11, XP-008012824, pp. 485-491, “Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil and Mustard Oil in Patients With Suspected Acute Myocardial Infarction: The Indian Experiment of Infact Survival”, 1997.
E. Guallar, et al., Arteriosclerosis, Thrombosis, and Vascular Biology 19, XP-001134928, pp. 1111-1118, “Omega-3 Fatty Acids in Adipose Tissue and Risk of Myocardial Infarction: the Euramic Study”, 1999.
P. McLennan, et al., European Journal of Pharmacology 300, XP-001134929, pp. 83-89, The Cardiovascular Protective Role of Docosahexaenoic Acid, 1996.
T. Rissanen, et al., Circulation, vol. 102, No. 22, XP-001134935, pp. 2677-2679, “Fish Oil-Derived Fatty Acids, Docosahexaenoic Acid and Docosapentaenoic Acid, and the Risk of Acute Coronary Events”, Nov. 28, 2000.
T. H. Rissanen, et al., Circulation, vol. 98, No. 17, XP-008012807, p. 2823, “Fish Oil-Derived Fatty Acids, Docosahexaenoic Acid and Docosapentaenoic Acid, and the Risk of Acute Myocardial Infarction”, Oct. 27, 1998.
Jahangiri, et al., “Restoration of Synchronous Contractile Activity by n-3 PUFAs in Atrial Cardiomyocytes”,Journal of Molecular and Cellular Cardiology, vol. 31, No. 1, A6 (1999).
Jahangiri, et al., “Termination of Asynchronous Contractile Activity in Rat Atrial Myocytes by n-3 Polyunsaturated Fatty Acids”,Molecular and Cellular Biochemistry, vol. 206, pp. 33-41 (Mar. 2000).
J. Kang and A. Leaf, “Protectice effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes,”European Journal of Pharmacology, vol. 297, No. 1-2, pp. 97-106 (1996).
Maixent, et al., “Remodeling of Na, K-ATPase, and Membrane Fluidity After Atrial Fibrillation in Sheep”,Journal of Receptors and Signal Transduction, vol. 22, Nos. 1-4, pp. 201-211 (2002; online publication date Jan. 12, 2002).
Siclari, et al., “Long Chain n 3 Fatty Acids Can Prevent Paroxysmal Atrial Fibrillation”,Circulation, vol. 106, No. 19 Suppl., pp. II 635 (Nov. 5, 2002).
Declaration of Cordelia Slaughter, dated Nov. 28, 2006, regarding Siclari et al., “Long Chain n 3 Fatty Acids Can Prevent Paroxysmal Atrial Fibrillation”, Circulation, vol. 106, No. 19 Suppl. pp. II 635.
US2008-0269331 (U.S. Appl. No. 11/984,485), Office Action dated Dec. 24, 2008 (7 total pages).
EP 1157692B1 Notice of Opposition by IBSA Institut Biochimique S.A., Jul. 5, 2006, pp. 1-12 (e.g., pp. 9-10, section C).
EP 1157692B1 Notice of Opposition by Pronova Biocare A.S., Jul. 5, 2006, pp. 1-24 (e.g., p. 22, section 3.17).
EP 1157692B1 Contestment of Opposition by Pro Aparts-Investimentos e Consultoria LDA, Apr. 11, 2007, pp. 1-24 and Annex 1 pp. 1-7, Annex 2, pp. 1-7, Annex 3 pp. 1-7, Annex 4 pp. 1-7 (e.g., p. 3 section 5; p. 15 section 9.3; pp. 23-24, section 9.4.8).
L. Frost et al.; n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study; Am J Clin Nutr 2005; 81:50-4.
D. Mozaffarian et al.; Fish intake and risk of incident atrial fibrillation; Circulation 2004; Jul. 27; 110(4):368-73.
Swann et al., Clinical Drug Investigation 15 (6), 473-482, 1998.
Henley, III Raymond J
Kinzig Charles M.
Pro Aparts Investimentos E Consultoria LDA
Sauermelch Loretta J.
Scrivner Alan
LandOfFree
Use of polyunsaturated fatty acid for the primary prevention... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of polyunsaturated fatty acid for the primary prevention..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of polyunsaturated fatty acid for the primary prevention... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4148299